Baxter Presents Clinical Efficacy Results from Phase III Study of Seasonal Flu Vaccine (Business Wire via Yahoo! Finance)
March 11, 2010 — JesseDEERFIELD, Ill.—-Baxter International Inc. , in conjunction with DynPort Vaccine Company LLC , a CSC Company , today presented Phase III study data measuring the clinical efficacy for PREFLUCEL, a trivalent seasonal influenza candidate vaccine.
View original post here:
Baxter Presents Clinical Efficacy Results from Phase III Study of Seasonal Flu Vaccine (Business Wire via Yahoo! Finance)